INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 273 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2023. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,747,944 | -7.0% | 379,112 | +13.0% | 0.00% | 0.0% |
| Q2 2023 | $21,238,922 | -13.8% | 335,422 | -26.3% | 0.00% | -20.0% |
| Q1 2023 | $24,644,423 | +31.4% | 455,114 | +28.4% | 0.01% | +25.0% |
| Q4 2022 | $18,756,594 | -37.7% | 354,433 | -45.2% | 0.00% | -42.9% |
| Q3 2022 | $30,116,000 | -16.2% | 647,246 | +2.9% | 0.01% | -12.5% |
| Q2 2022 | $35,920,000 | +22.6% | 629,294 | +31.5% | 0.01% | +33.3% |
| Q1 2022 | $29,293,000 | +137.9% | 478,718 | +103.5% | 0.01% | +200.0% |
| Q4 2021 | $12,313,000 | -43.7% | 235,243 | -59.9% | 0.00% | -60.0% |
| Q3 2021 | $21,882,000 | -27.0% | 586,986 | -20.1% | 0.01% | -28.6% |
| Q2 2021 | $29,987,000 | +8.2% | 734,616 | -10.1% | 0.01% | 0.0% |
| Q1 2021 | $27,722,000 | +44.4% | 817,039 | +35.3% | 0.01% | +40.0% |
| Q4 2020 | $19,199,000 | +413.2% | 603,735 | +314.0% | 0.01% | +400.0% |
| Q3 2020 | $3,741,000 | -75.1% | 145,816 | -75.1% | 0.00% | -80.0% |
| Q2 2020 | $15,051,000 | +117.6% | 586,329 | +30.3% | 0.01% | +150.0% |
| Q1 2020 | $6,917,000 | -4.5% | 450,064 | +113.2% | 0.00% | 0.0% |
| Q4 2019 | $7,243,000 | +745.2% | 211,104 | +83.9% | 0.00% | – |
| Q3 2019 | $857,000 | -53.6% | 114,799 | -19.3% | 0.00% | – |
| Q2 2019 | $1,846,000 | +38.1% | 142,230 | +29.5% | 0.00% | – |
| Q1 2019 | $1,337,000 | +36.6% | 109,788 | +27.8% | 0.00% | – |
| Q4 2018 | $979,000 | -32.9% | 85,929 | +27.8% | 0.00% | – |
| Q3 2018 | $1,459,000 | +19.1% | 67,242 | -3.1% | 0.00% | – |
| Q2 2018 | $1,225,000 | -6.1% | 69,358 | +12.0% | 0.00% | – |
| Q1 2018 | $1,304,000 | -3.2% | 61,951 | -33.4% | 0.00% | – |
| Q4 2017 | $1,347,000 | -62.5% | 93,049 | -59.1% | 0.00% | -100.0% |
| Q3 2017 | $3,592,000 | -50.2% | 227,624 | -60.8% | 0.00% | -50.0% |
| Q2 2017 | $7,213,000 | +233.3% | 580,770 | +336.1% | 0.00% | +100.0% |
| Q1 2017 | $2,164,000 | +72.2% | 133,184 | +59.9% | 0.00% | – |
| Q4 2016 | $1,257,000 | -68.8% | 83,300 | -68.5% | 0.00% | -100.0% |
| Q3 2016 | $4,029,000 | +14.9% | 264,360 | +192.6% | 0.00% | 0.0% |
| Q2 2016 | $3,508,000 | +406.9% | 90,350 | +263.2% | 0.00% | – |
| Q1 2016 | $692,000 | -52.7% | 24,876 | -8.5% | 0.00% | – |
| Q4 2015 | $1,462,000 | +35.4% | 27,179 | +0.7% | 0.00% | – |
| Q3 2015 | $1,080,000 | -34.6% | 26,979 | -47.8% | 0.00% | -100.0% |
| Q2 2015 | $1,652,000 | +373.4% | 51,708 | +254.1% | 0.00% | – |
| Q1 2015 | $349,000 | +134.2% | 14,604 | +34.2% | 0.00% | – |
| Q3 2014 | $149,000 | -65.7% | 10,881 | -57.7% | 0.00% | – |
| Q2 2014 | $434,000 | – | 25,729 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |